16th Jul 2009 07:00
Stock Exchange announcement
FOR release: 7.00am - Thursday 16 July 2009
CELSIS INTERNATIONAL PLC
("Celsis", "the Company" or "the Group")
Annual Information update
16 July 2009: Celsis International plc, the international life sciences products and laboratory services company, is pleased to provide an annual information update, in accordance with the requirements of the Prospectus Rule 5.2. This update refers to information that has been published or made available by the Company to the public over the twelve months preceding this announcement. To avoid a statement of unnecessary length information is referred to in this update rather than included in full.
In accordance with Rule 5.2.7 of the Prospectus Rules, the information referred to in this update was up to date at the time the information was published but some information may now be out of date. This annual information update does not constitute an offer of securities addressed to any person and should not be relied on by any person.
Announcements made via the Regulatory News Service ("RNS"), a Regulatory Information Service ("RIS").
|
Date of Publication |
Regulatory Headline |
|
30 June 2009 |
Annual Report and Accounts |
|
24 June 2009 |
Final Results |
|
15 May 2009 |
Directorate Change |
|
22 April 2009 |
Appointment of Broker and Financial Adviser |
|
30 March 2009 |
Pre Close Trading Update |
|
18 March 2009 |
Holding(s) in Company |
|
12 March 2009 |
Holding(s) in Company |
|
11 March 2009 |
Holding(s) in Company |
|
11 March 2009 |
Holding(s) in Company |
|
9 March 2009 |
Holding(s) in Company |
|
2 March 2009 |
Holding(s) in Company |
|
23 February 2009 |
Holding(s) in Company |
|
18 February 2009 |
Holding(s) in Company |
|
13 February 2009 |
Holding(s) in Company |
|
12 February 2009 |
Interim Management Statement |
|
23 January 2009 |
Holding(s) in Company |
|
17 December 2008 |
Holding(s) in Company |
|
16 December 2008 |
Holding(s) in Company |
|
14 November 2008 |
Purchase of treasury shares |
|
12 November 2008 |
Notice of Results |
|
3 November 2008 |
Holding(s) in Company |
|
28 October 2008 |
Holding(s) in Company |
|
22 October 2008 |
Holding(s) in Company |
|
21 October 2008 |
Notice of Results |
|
17 October 2008 |
Holding(s) in Company |
|
6 October 2008 |
Holding(s) in Company |
|
3 October 2008 |
Holding(s) in Company |
|
29 September 2008 |
Holding(s) in Company |
|
26 September 2008 |
Pre Close Trading Update |
|
12 September 2008 |
Holding(s) in Company |
|
11 September 2008 |
Holding(s) in Company |
|
5 September 2008 |
Holding(s) in Company |
|
8 August 2008 |
Holding(s) in Company |
|
25 July 2008 |
Share Options and Treasury Shares |
|
23 July 2008 |
AGM Resolutions Passed |
|
23 July 2008 |
Interim Management Statement |
|
18 July 2008 |
Annual Information Update |
Copies of all announcements can be obtained from the Regulatory News Service of the London Stock Exchange.
2. Documents filed at Companies House
The documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated. Copies of these documents can be obtained from Companies House.
|
Date |
Document type |
Description |
|
3 July 2009 |
363a |
Annual Return |
|
6 June 2009 |
288a |
Director Appointed |
|
28 May 2009 |
288b |
Director Resigned |
|
28 May 2009 |
288b |
Director Resigned |
|
27 February 2009 |
RES01 |
Disapply Pre-Emption Rights Auth Allot Of Security Increase Authorised Share Capital Adopt Articles |
|
26 September 2008 |
AA |
Group Of Companies' Accounts |
3. Documents sent to Shareholders
The documents listed below have been despatched by the Company to holders of its securities on or around the following dates.
|
Date |
Description |
|
30 June 2009 |
2009 Annual Report and Accounts |
|
30 June 2009 |
Notice of Annual General Meeting |
|
5 December 2008 |
2008 Interim Report |
4. Documents submitted to the UK Listing Authority
Copies of the following documents have been submitted to the UK Listing Authority for inspection at their Document Viewing Facility on or around the following dates and can be obtained from the Company Secretary, Celsis International plc, 1010 Cambourne Business Park, Cambourne, Cambridge, CB23 6DP.
|
Date |
Description |
|
15 December 2008 |
2008 Interim Report |
|
Enquiries: |
|
|
Celsis International plc |
Tel: +44 (0) 1223 598 428 |
|
Christian Madrolle, Company Secretary |
|
|
Robyn LaLonde, Executive Assistant to CEO |
|
|
Financial Dynamics |
Tel: +44 (0) 20 7831 3113 |
|
Jonathan Birt |
|
|
Susan Quigley |
Notes to editors
Celsis International plc
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis business has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange's Main Market (CEL.L).
Celsis Rapid Detection utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market.
Celsis Analytical Services provides cost effective outsourced analytical laboratory services to the pharmaceutical and consumer products industries. Its comprehensive service offerings include a full spectrum of laboratory services used in the ongoing manufacture of our customers' products ranging from analytical chemistry and biological sciences to stability storage and testing.
Celsis In Vitro Technologies (IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical industry. IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or research on those compounds that will not be properly metabolised by the human liver.
Further information can be found on its website at www.celsis.com.
Related Shares:
Celadon Pharmaceuticals